Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (435)	1/14/2008 7:12:09 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 447

Jon: SLV320 from Solvay, purchased by OSI from Cadus (verification from Solvay that the molecule originated at Cadus). clinicaltrials.gov I'll post more later, showing the trail. Goddard planned to spin out diabetes and the adenosine receptor program to Prosidion, and then all signs of a OSI/SLV320 relationship simply went poof. No sweat, but the OSI-Cadus deal bears milestone and royalty obligations. Unless, that is, Goddard, Glass and Icahn have conspired to make the molecule go away. The poof actually pre-dated the Tarceva windfall, the only thing that has saved Goddard's sorry business development ass. Best! Rick